| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC65117 | SJ-07 Featured |
|
|
| DC65118 | SJ-06 Featured |
|
|
| DC65119 | SJ-05 Featured |
|
|
| DC65120 | SJ-04 Featured |
|
|
| DC65121 | SJ-03 Featured |
|
|
| DC65122 | tert-butyl (3S,4S)-3-fluoro-4-hydroxypiperidine-1-carboxylate Featured |
.png)
|
|
| DC60443 | PYR01 Featured | Pyr01 is a targeted activator of cell kill (TACK) and shows more than 300-fold more potent than doravirine and also retains reverse transcriptase (RT) inhibition activity within about 3-fold of doravirine. |
|
| DC65123 | (R)-1-(3-Nitro-5-(trifluoromethyl)phenyl)ethan-1-amine hydrochloride Featured |
.png)
|
|
| DC65124 | 1,2-Benzenediamine, 4-[6-(dimethylamino)-4-pyrimidinyl]- Featured |
|
|
| DC65125 | CPD2500-A3 Featured |
|
|
| DC65126 | Potassium (4-Boc-piperazin-1-yl)methyltrifluoroborate Featured |
.png)
|
|
| DC65127 | (αR)-α-Methyl-N-(2,2,2-trifluoroethyl)-1H-indole-3-ethanamine Featured |
|
|
| DC65128 | 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE Featured |
|
|
| DC65129 | CPD3325-A8 Featured |
|
|
| DC65130 | DIPHENYL ((6-METHYLPYRIDIN-2-YL)(PHENYLAMINO)METHYL)PHOSPHONATE Featured |
|
|
| DC65131 | 6-Bromo-1,5-dimethylpyrimidine-2,4(1H,3H)-dione Featured |
|
|
| DC65132 | 2-chloro-6-methyl-4-(trifluoromethyl)nicotinonitrile Featured |
|
|
| DC65133 | (aS)-a-methyl-1H-Indole-3-ethanamine Featured |
|
|
| DC65134 | 6-bromo-3-chloro-7-fluoro-2-methyl-1,5-naphthyridin-4-ol Featured |
|
|
| DC65135 | 3-(3-Fluorophenyl)-5-nitro-4-pyridinamine Featured |
|
|
| DC65136 | N-(5-bromopyridin-3-yl)-3-methylbutanamide Featured |
|
|
| DC65137 | 5-(3-fluorophenyl)pyridine-3,4-diamine Featured |
|
|
| DC65138 | CPD109174-A4 Featured |
.png)
|
|
| DC65139 | 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 1,4-dihydro-5-methyl- (9CI) Featured |
|
|
| DC65140 | IHMT-PI3Kδ-372 S-isomer Featured |
.png)
|
|
| DC65141 | METHYL 5-CHLORO-7-(TRIFLUOROMETHYL)THIENO[3,2-B]PYRIDINE-3-CARBOXYLATE Featured |
|
|
| DC65142 | 6-Methoxynicotinaldehyde Featured |
|
|
| DC65143 | 2-(Piperazin-2-yl)acetonitrile dihydrochloride Featured |
|
|
| DC86601 | Lipid 8 Featured | Lipid 8 iLNPs were used to deliver CRISPR-Cas9 mRNA and sgRNA which targeted to the PLK1 gene. The safety and excellent intracerebral diffusion performance of lipid 8 iLNPs ensured that the survival of murine glioblastoma multiforme (GBM) mice was extended. The median survival was extended by approximately 50% and the overall survival was increased by 30%. The treatment of metastatic adenocarcinoma was executed by the EGFRtargeted lipid 8 iLNPs. These iLNPs possessed the ability of tumor targeting, which could increase the accumulation of CRISPR-Cas9 mRNA and sgRNA within the tumor cells. After a single intraperitoneal administration, 80% PLK1 gene was edited and the overall survival of mice with high-grade ovarian cancer malignant ascites was enhanced by 80% . These results demonstrate the clinical potential of CRISPR-Cas9 gene editing system can be delivered by iLNPs for treating tumors, and provide new ideas for tumor gene therapy. |
|
| DC65144 | CPD10000-A3 Featured |
|
